Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Siamak Moradian & Hooshang Faghihi & Babak Sadeghi & Niloofar Piri & Hamid Ahmadieh & Masoud Soheilian & Mohammad Hossein Dehghan & Mohsen Azarmina &
- چاپ و سال / کشور: 2010
Description
Background The goal of this work is to compare the visual and anatomical (central macular thickness; CMT) outcomes of intravitreal bevacizumab (IVB) injections relative to sham treatment in eyes with acute (less than 3 months in duration) branch retinal vein occlusion (BRVO). Methods In a double-masked randomized clinical trial (RCT), patients with acute BRVO were randomly assigned to one of two treatment groups: IVB (two injections of 1.25 mg IVB 6 weeks apart) or sham treatment. Primary outcome measures included changes in best-corrected visual acuity (BCVA) and CMT in optical coherence tomography (OCT) during followup (FU) examinations. Any complications secondary to injections were considered secondary outcomes. FU results after 6 and 12 weeks are reported. Results Eighty-one eyes (43 OD) of 81 patients (47 females) were enrolled in the study. Forty-two patients were enrolled in the IVB group, and 39 patients were enrolled in the sham group.Visual acuity and CMTimproved in the IVB group after week 6 (two Snellen lines and 262 ìm, respectively) and week 12 (three Snellen lines and 287 ìm, respectively). After week 6, visual improvements in the IVB group were significantly increased relative to that of the sham group. However, visual improvements at week 12 were not significantly different between the two groups (1.5 Snellen lines visual improvement in the sham group at week 12). Conclusions In acute BRVO, two IVB injections resulted in significant improvement of vision and CMT at 6 weeks relative to the sham group. However, the visual improvements in the IVB group were not significantly different from those in the sham group at 12 weeks. IVB injections accelerate an initial improvement of visual acuity but do not have any significant effects on vision after 12 weeks
Graefes Arch Clin Exp Ophthalmol (2011) 249:193–200 DOI 10.1007/s00417-010-1440-8 Received: 24 January 2010 / Revised: 1 May 2010 / Accepted: 16 June 2010 / Published online: 18 August 2010
